Friday, December 2, 2011

Opko (OPK) (PCG) (RUE) (FNSR) (GES) Price Targets Changed

Opko Health Inc. (NYSE: OPK), PG&E Co. (NYSE: PCG), Rue21 (NYSE: RUE), Finisar (NASDAQ: FNSR) and Guess Inc. (NYSE: GES) had price targets on them adjusted by analysts.

Opko Health Inc. (OPK) had its price target raised by Ladenburg Thalmann from $6.00 to $8.50. They have a “Buy” rating on the company.

PG&E Co. (NYSE: PCG) had its price target lowered by Citigroup (NYSE:C) to $47.00. They have a “Buy” rating on the company.

Rue21 (RUE) had its price target lowered by Jefferies (NYSE:JEF) to $27.00. They have a “Hold” rating on the company.

Finisar (FNSR) had its price target lowered by Stifel Nicolaus from $30.00 to $27.00. They have a “Buy” rating on the company.

Guess Inc. (GES) had its price target lowered by Piper Jaffray (NYSE:PJC) to $33.00.

2 comments:

  1. Opko has perhaps one the most attractive "revenue ramps" (according to the likes of Mad Moneys Jim Crammer and others) in the bio-tech sector. Diagnostics account for over 500 billion in revenue world wide, and the technology that opko possesses is nothing short of a "game changer". For example a simple vitamin d test alone, annually world-wide is performed over est. by 2012 500 million times (500,000 by the Mayo clinic alone in 2009) @ an average of $50.00 per test, you can see why this company's true value lies in its potential revenues. Opko can currently perform over 20 mainstream diagnostics tests which use to take days or weeks to conclude, now in-house within 10 minutes with greater accuracy, reliability and with less evasiveness than ever before. With only a 1.8 billion dollar market cap.....this stock is "dirt-cheap". I think that by the summer of 2012 Opko (OPK) will be trading well above the $22.00 to $26.00 price level on anticipated revenues. Please research for yourself.

    The CEO of Opko Health is Dr. Phillip Frost. He has an excellent histry of buying, running than selling small bio-tech companies at HUGE profits for early stock holders.... (TEVA) being his last venture before Opko. Over 6000% was made by early investors. Opko will be no exception. This man is not only a genius , but he is also a brilliant, billionaire businessman with an unmatched ability to seek out undervalued bio-tech companies like Claros and run them in such a way as to making them irresistible acquisitions by big pharma companies.

    Opko, with Dr. Frost at its' helm, will soon acquire a large percentage of the 500 billion dollar market share for diagnostics and soon be priced to reflect this revenue. By then I am sure that the stock price will be well into the $50.00 price range or more.

    ReplyDelete
  2. Opko has perhaps one the most attractive "revenue ramps" (according to the likes of Mad Moneys Jim Crammer and others) in the bio-tech sector. Diagnostics account for over 500 billion in revenue world wide, and the technology that opko possesses is nothing short of a "game changer". For example a simple vitamin d test alone, annually world-wide is performed over est. by 2012 500 million times (500,000 by the Mayo clinic alone in 2009) @ an average of $50.00 per test, you can see why this company's true value lies in its potential revenues. Opko can currently perform over 20 mainstream diagnostics tests which use to take days or weeks to conclude, now in-house within 10 minutes with greater accuracy, reliability and with less evasiveness than ever before. With only a 1.8 billion dollar market cap.....this stock is "dirt-cheap". I think that by the summer of 2012 Opko (OPK) will be trading well above the $22.00 to $26.00 price level on anticipated revenues. Please research for yourself.

    The CEO of Opko Health is Dr. Phillip Frost. He has an excellent histry of buying, running than selling small bio-tech companies at HUGE profits for early stock holders.... (TEVA) being his last venture before Opko. Over 6000% was made by early investors. Opko will be no exception. This man is not only a genius , but he is also a brilliant, billionaire businessman with an unmatched ability to seek out undervalued bio-tech companies like Claros and run them in such a way as to making them irresistible acquisitions by big pharma companies.

    Opko, with Dr. Frost at its' helm, will soon acquire a large percentage of the 500 billion dollar market share for diagnostics and soon be priced to reflect this revenue. By then I am sure that the stock price will be well into the $50.00 price range or more.

    ReplyDelete